<DOC>
	<DOCNO>NCT02078609</DOCNO>
	<brief_summary>This study ass safety preliminary efficacy escalate dos LGH447 monotherapy AML MDS LGH447 combination midostaurin AML .</brief_summary>
	<brief_title>A Safety Efficacy Study LGH447 Patients With Acute Myeloid Leukemia ( AML ) High Risk Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Inclusion Criteria Male female patient ≥18 year age present one following : LGH447 monotherapy arm Refractory/Relapsed AML follow 2 prior therapy , previously untreated AML patient candidate standard therapy . High high risk MDS accord revise International Prognostic Scoring System ( rIPSS ) fail prior therapy , azacitidine decitabine Patients rIPSS score &gt; 4.5 LGH447 midostaurin combination arm Refractory/Relapsed AML follow 2 prior therapy , previously untreated AML patient candidate standard therapy . AML patient may either FLT3 wild type FLT3ITD/TKD mutant disease , FLT3 mutation status need define study entry . For AML patient , peripheral blast count &lt; 50,000 blasts/mm3 For MDS patient ; Platelet count &gt; 25,000/mm3 Neutrophils &gt; 500/mm3 Blood transfusion allow maintain clinically adequate hemoglobin hematocrit level Patients active central nervous system ( CNS ) disease eligible participate may treat concurrently intrathecal ( intra Ommaya ) chemotherapy Patients maintain prophylactic antibiotic eligible participate long agent comply list approve concomitant medication Performance status ≤ 2 Meet lab criterion Exclusion Criteria Systemic antineoplastic therapy ( include unconjugated therapeutic antibody toxin immunoconjugates ) experimental therapy within 7 day 5 halflives , whichever longer , first dose LGH447 monotherapy LGH447 combination midostaurin Radiotherapy wide field radiation within 28 day radiotherapy limited field radiation palliation within 7 day first dose LGH447 monotherapy LGH447 combination midostaurin Patients receive CNS irradiation meningeal leukemia , except radiotherapy occur &gt; 3 month previously Major surgery within 4 week first dose LGH447 monotherapy LGH447 combination midostaurin Ongoing therapy corticosteroid great 10 mg prednisone equivalent per day . Inhaled topical steroid permit Patients currently receive hydroxyurea control peripheral blood leukemic blast discontinue least 48 hour prior obtain PD biomarkers screening/baseline study Patients currently receive treatment prohibit medication discontinue least one week prior start treatment LGH447 monotherapy LGH447 combination midostaurin Active infection require systemic therapy severe infection , include pneumonia , within 2 week first dose LGH447 monotherapy LGH447 combination midostaurin Known human immunodeficiency virus ( HIV ) positive Corrected QT interval ( QTc ) &gt; 450 millisecond ( m ) males &gt; 470 millisecond ( m ) females baseline electrocardiogram ( ECG ) ( use correct QT interval use Fridericia [ QTcF ] local standard ) . Uncontrolled cardiovascular condition , include ongoing cardiac arrhythmia , congestive heart failure , angina , myocardial infarction within past 6 month Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AML ,</keyword>
	<keyword>MDS ,</keyword>
	<keyword>PIM ,</keyword>
	<keyword>LGH447 ,</keyword>
	<keyword>acute myelod leukemia ,</keyword>
	<keyword>myelodysplastic syndrome ,</keyword>
	<keyword>midostaurin ,</keyword>
	<keyword>PKC412</keyword>
</DOC>